Marengo’s precision, Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models
Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) to treat PD(L)1 resistant “cold” cancers
First disclosure of preliminary Phase 1 clinical results from the STARt-001 study
CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced first-in-human clinical data for its lead selective T cell activator, invikafusp alfa (STAR0602), will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 8-10th, 2024 in Houston, Texas.
Presentation details:
Title: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
Conference: 39th SITC Annual Meeting
Abstract Number: LBA-1470
Session Title: Late-Breaking Abstract Session 2
Session Date and Time: Saturday, November 9, 2024, 11:45 AM – 12:15 PM
Presenter: James L. Gulley, M.D., Ph.D. (National Cancer Institute, Bethesda, Maryland, USA)
About Marengo TherapeuticsMarengo Therapeutics, Inc. is a clinical-stage biotechnology company advancing innovative T cell-targeting therapies to revolutionize cancer treatment. The company’s proprietary Selective T Cell Activation Repertoire (STAR™) platform is designed to selectively engage distinct T cell subsets by targeting the Vβ chain of the T cell receptor (TCR), empowering the immune system to combat cancer. To learn more, visit marengotx.com.
About the STAR™ PlatformMarengo’s STAR™ platform is a multi-specific antibody-fusion technology derived from a proprietary library of antibodies targeting germline-encoded variable Vβ regions of the TCR. These antibodies are fused with T cell co-stimulatory moieties to promote durable anti-tumor immune responses.
About Invikafusp alfa (STAR0602)Invikafusp alfa (STAR0602) is the lead candidate from Marengo’s STAR™ platform. It is designed to selectively activate a common Vβ T cell subset found in all cancers by combining a non-clonal mode of TCR activation with a T cell co-stimulatory signal in a single molecule. This innovative approach promotes the expansion of clonally diverse, effector memory Vβ T cells, enhancing anti-tumor immunity and enabling durable tumor clearance. Extensive preclinical studies demonstrate STAR0602’s potent anti-tumor activity in both mouse and human ex vivo models via a novel mechanism of action.
About the STARt-001 Clinical StudySTARt-001 is a Phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary efficacy of invikafusp alfa as a monotherapy in biomarker-selected patients with advanced antigen-rich solid tumors, including PD-1 refractory and rare tumor types. The trial consists of two parts: Phase 1 dose escalation and Phase 2 dose expansion. For more information, visit clinicaltrials.gov (Identifier: NCT05592626).
Patients interested in participating in this study at the National Cancer Institute (NCI) can contact NCI’s toll-free number: 1-800-4-CANCER (1-800-422-6237) (TTY: 1-800-332-8615), visit the website at https://trials.cancer.gov, or email [email protected].
Marengo Contacts:Media:Peg Rusconi | [email protected]
Investors:Svetlana Makhni | [email protected]
SOURCE Marengo Therapeutics
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+Newsrooms &Influencers
9k+Digital MediaOutlets
270k+JournalistsOpted In